MyFibroScan Status

While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. - Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy.  High clinical performances are demonstrated in large external validation cohorts from different geographical origins. - Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters.  High clinical performances are demonstrated in large external validation cohorts from different geographical origin. - Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2.  Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.  Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).  The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.  Scores enhance Fibroscan® liver disease assessment with biological markers.  FibroScan® is the non-invasive solution for comprehensive management of liver health.  Scores are presented as educational services intended for licensed healthcare professionals.  It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma.  Several publications advocate the use of Fast™.